Titre : Mitogen-Activated Protein Kinase 3

Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Optometrists

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dysfonction de MAPK3 ?

Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés.
Kinases Signalisation cellulaire
#2

Quels tests sont utilisés pour évaluer MAPK3 ?

Les tests de phosphorylation et les analyses protéomiques sont courants.
Protéomique Phosphorylation
#3

Y a-t-il des biomarqueurs associés à MAPK3 ?

Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3.
Biomarqueurs Protéines
#4

MAPK3 est-elle impliquée dans des maladies spécifiques ?

Oui, elle est liée à des cancers et des maladies inflammatoires.
Cancers Maladies inflammatoires
#5

Quels symptômes peuvent indiquer un problème avec MAPK3 ?

Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques.
Symptômes Fatigue

Symptômes 5

#1

Quels symptômes sont liés à une activation excessive de MAPK3 ?

Une activation excessive peut entraîner une inflammation et des douleurs.
Inflammation Douleurs
#2

MAPK3 affecte-t-elle le système immunitaire ?

Oui, elle joue un rôle dans la régulation de la réponse immunitaire.
Système immunitaire Réponse immunitaire
#3

Quels signes cliniques sont associés à MAPK3 ?

Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître.
Éruptions cutanées Troubles métaboliques
#4

Y a-t-il des symptômes neurologiques liés à MAPK3 ?

Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3.
Troubles neurologiques Dysfonction
#5

Comment la MAPK3 influence-t-elle le stress cellulaire ?

Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose.
Stress cellulaire Apoptose

Prévention 5

#1

Comment prévenir les dysfonctionnements de MAPK3 ?

Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé.
Mode de vie sain Nutrition
#2

Y a-t-il des habitudes à éviter pour MAPK3 ?

Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé.
Tabagisme Graisses saturées
#3

Le stress peut-il affecter MAPK3 ?

Oui, le stress chronique peut perturber la signalisation de MAPK3.
Stress Signalisation
#4

Des exercices spécifiques aident-ils MAPK3 ?

Des exercices réguliers peuvent améliorer la régulation de MAPK3.
Exercices Régulation
#5

La gestion du poids influence-t-elle MAPK3 ?

Maintenir un poids santé peut aider à réguler l'activité de MAPK3.
Gestion du poids Santé

Traitements 5

#1

Quels traitements ciblent MAPK3 ?

Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers.
Inhibiteurs Cancers
#2

La thérapie génique peut-elle corriger MAPK3 ?

La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3.
Thérapie génique Mutations
#3

Quels médicaments affectent la voie MAPK3 ?

Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3.
Médicaments Inhibiteurs de MEK
#4

Y a-t-il des traitements naturels pour MAPK3 ?

Certaines plantes médicinales peuvent influencer la signalisation de MAPK3.
Plantes médicinales Signalisation
#5

Comment la nutrition influence-t-elle MAPK3 ?

Une alimentation riche en antioxydants peut moduler l'activité de MAPK3.
Nutrition Antioxydants

Complications 5

#1

Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?

Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir.
Complications Inflammation chronique
#2

MAPK3 est-elle liée à des maladies auto-immunes ?

Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes.
Maladies auto-immunes Anomalies
#3

Comment MAPK3 affecte-t-elle le cancer ?

Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer.
Cancer Activation aberrante
#4

Y a-t-il des risques cardiovasculaires liés à MAPK3 ?

Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires.
Risques cardiovasculaires Maladies cardiovasculaires
#5

MAPK3 peut-elle influencer le vieillissement ?

Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré.
Vieillissement Dysfonctionnements

Facteurs de risque 5

#1

Quels facteurs de risque sont associés à MAPK3 ?

Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus.
Obésité Tabagisme
#2

L'âge influence-t-il l'activité de MAPK3 ?

Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire.
Âge Signalisation cellulaire
#3

Y a-t-il des prédispositions génétiques pour MAPK3 ?

Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3.
Prédispositions génétiques Mutations
#4

Le mode de vie influence-t-il MAPK3 ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques.
Mode de vie sédentaire Mauvaise alimentation
#5

Des infections peuvent-elles affecter MAPK3 ?

Certaines infections virales peuvent perturber la signalisation de MAPK3.
Infections virales Perturbation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes", "headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Extracellular Signal-Regulated MAP Kinases", "url": "https://questionsmedicales.fr/mesh/D048049", "about": { "@type": "MedicalCondition", "name": "Extracellular Signal-Regulated MAP Kinases", "code": { "@type": "MedicalCode", "code": "D048049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.567.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3", "alternateName": "Mitogen-Activated Protein Kinase 3", "code": { "@type": "MedicalCode", "code": "D048052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Juan Wang", "url": "https://questionsmedicales.fr/author/Juan%20Wang", "affiliation": { "@type": "Organization", "name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea." } }, { "@type": "Person", "name": "Mohammad Shafiq", "url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Kumaravelu Jagavelu", "url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Neeraj Kumar Verma", "url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Jimut Kanti Ghosh", "url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Attitudes and knowledge of myopia management by Spanish optometrists.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37596425", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10792-023-02835-7" } }, { "@type": "ScholarlyArticle", "name": "Optometrist's perspectives of Artificial Intelligence in eye care.", "datePublished": "2022-09-20", "url": "https://questionsmedicales.fr/article/36137899", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.optom.2022.06.006" } }, { "@type": "ScholarlyArticle", "name": "Nd:YAG Laser Capsulotomy: Efficacy and Outcomes Performed by Optometrists.", "datePublished": "2023-08-08", "url": "https://questionsmedicales.fr/article/37594749", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/OPX.0000000000002057" } }, { "@type": "ScholarlyArticle", "name": "Prescribing patterns for hyperopia: an insight of the optometrist perspective and practice.", "datePublished": "2024-05-28", "url": "https://questionsmedicales.fr/article/38807053", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-024-03496-5" } }, { "@type": "ScholarlyArticle", "name": "Dry eye clinical practice patterns of UK optometrists.", "datePublished": "2023-07-15", "url": "https://questionsmedicales.fr/article/37455178", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clae.2023.101889" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Mitogen-Activated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D020928" }, { "@type": "ListItem", "position": 7, "name": "Extracellular Signal-Regulated MAP Kinases", "item": "https://questionsmedicales.fr/mesh/D048049" }, { "@type": "ListItem", "position": 8, "name": "Mitogen-Activated Protein Kinase 3", "item": "https://questionsmedicales.fr/mesh/D048052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3", "description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitogen-Activated Protein Kinase 3", "description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitogen-Activated Protein Kinase 3", "description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitogen-Activated Protein Kinase 3", "description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitogen-Activated Protein Kinase 3", "description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3", "description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Optometrists#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de MAPK3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer MAPK3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de phosphorylation et les analyses protéomiques sont courants." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à MAPK3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3." } }, { "@type": "Question", "name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des cancers et des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner une inflammation et des douleurs." } }, { "@type": "Question", "name": "MAPK3 affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à MAPK3 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3." } }, { "@type": "Question", "name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements de MAPK3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter pour MAPK3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé." } }, { "@type": "Question", "name": "Le stress peut-il affecter MAPK3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation de MAPK3." } }, { "@type": "Question", "name": "Des exercices spécifiques aident-ils MAPK3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3." } }, { "@type": "Question", "name": "La gestion du poids influence-t-elle MAPK3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quels traitements ciblent MAPK3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger MAPK3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3." } }, { "@type": "Question", "name": "Quels médicaments affectent la voie MAPK3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour MAPK3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle MAPK3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "MAPK3 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment MAPK3 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "MAPK3 peut-elle influencer le vieillissement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à MAPK3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus." } }, { "@type": "Question", "name": "L'âge influence-t-il l'activité de MAPK3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il MAPK3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Des infections peuvent-elles affecter MAPK3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber la signalisation de MAPK3." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 18/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Juan Wang

2 publications dans cette catégorie

Affiliations :
  • Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea.

Mohammad Shafiq

2 publications dans cette catégorie

Affiliations :
  • From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).

Kumaravelu Jagavelu

2 publications dans cette catégorie

Affiliations :
  • From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).

Neeraj Kumar Verma

2 publications dans cette catégorie

Affiliations :
  • Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.

Jimut Kanti Ghosh

2 publications dans cette catégorie

Affiliations :
  • Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.

Matthias Gaestel

2 publications dans cette catégorie

Affiliations :
  • Institute for Zellbiochemie, Medizinische Hochschule Hannover (MHH), Hanover, Germany (M.G.).

Kashif Hanif

2 publications dans cette catégorie

Affiliations :
  • From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).

Yu Liu

2 publications dans cette catégorie

Affiliations :
  • Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China.

Minchae Kim

1 publication dans cette catégorie

Affiliations :
  • Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Soongon Jeong

1 publication dans cette catégorie

Affiliations :
  • Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Chae Woo Lim

1 publication dans cette catégorie

Affiliations :
  • Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Sung Chul Lee

1 publication dans cette catégorie

Affiliations :
  • Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Tayeb Muhammad

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Jie Zhang

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Yalin Ma

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Yushun Li

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Fei Zhang

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. feizhang@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Yan Zhang

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Yan Liang

1 publication dans cette catégorie

Affiliations :
  • College of Horticulture, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
  • State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :

Kouichi Miura

1 publication dans cette catégorie

Affiliations :
  • Division of Gastroenterology, Department of Medicine Jichi Medical University School of Medicine Shimotsuke Tochigi Japan.

Sources (77 au total)

Attitudes and knowledge of myopia management by Spanish optometrists.

To investigate the knowledge, training and clinical practice of Spanish optometrists about preventing and controlling myopia progression.... A web-based questionnaire was distributed to Spanish optometrists through social networks, optometric professional bodies and one of the major Spanish optometrists' associations to assess practitioner... A total of 534 optometrists with a mean age of 40.8 ± 10.3 years completed the survey. Most respondents have been practicing optometry for more than 20 years (89.8%), report having actively treated ch... Spanish optometrists are very active in the management of myopia, especially by fitting orthokeratology lenses or dual-focus soft contact lenses for myopia control, but there is still potential for im...

Optometrist's perspectives of Artificial Intelligence in eye care.

The application of artificial intelligence (AI) in diagnosing and managing ocular disease has gained popularity as research highlights the utilization of AI to improve personalized medicine and health... Members of the American Academy of Optometry were sent an electronic invitation to complete a 17-item survey. Survey items assessed perceived advantages and concerns regarding AI using a 5-point Liker... A total of 400 optometrists completed the survey. The mean number of years since optometry school completion was 25 ± 15.1. Most respondents reported familiarity with AI (66.8%). Though half of optome... In this study, optometrists are optimistic about the use of AI in eye care, and willingness to incorporate AI in clinical practice also increased after the onset of the COVID-19 pandemic....

Nd:YAG Laser Capsulotomy: Efficacy and Outcomes Performed by Optometrists.

An increasing number of optometrists are performing Nd:YAG laser capsulotomy procedures; however, there is limited published information on the outcomes of these procedures.... This study aimed to assess the efficacy and safety of capsulotomy procedures performed by optometrists.... Subjects diagnosed with posterior capsule opacification causing reduced vision and subjective visual complaints were recruited for this study. A baseline examination was performed to ensure that the s... Subjects' Snellen visual acuity improved from an average of 20/40 to 20/23 ( P < .001) with no complications of increased intraocular pressure, inflammation, visually significant lens pitting, macular... Based on the outcomes of this study, YAG laser capsulotomies are effective treatments to improve patient vision that can be safely and effectively performed by optometrists....

Prescribing patterns for hyperopia: an insight of the optometrist perspective and practice.

To investigate the current prescribing patterns for correcting hyperopia among optometrists in clinical practice in Saudi Arabia and compare those to current international guidelines. And explore the ... This cross-sectional study employed 30 items online survey that encompass demographic data, current practice and cycloplegia use, numerical response to indicate the minimum level of hyperopia at which... A total of 104 optometrists responded to the survey (52 females and 52 males). They recruited from 35 cities across Saudi Arabia. Out of total, 44% of them considered cycloplegic refraction essential ... There are some matches between the international guidelines and the practice patterns that followed by optometrists in Saudi Arabia, however, the optometrists did not report that they are following th...

Dry eye clinical practice patterns of UK optometrists.

In light of the increased roles of optometrists working in primary care in the UK, this research study aimed to gain an insight into perceptions of dry eye disease (DED), knowledge and confidence in d... Links to an online survey were distributed to optometrists across the UK via optometry websites newsletters, conferences, and local optical committee data bases, between October 2021 and July 2022. Th... The survey was completed by 131 optometrists, with a broad range of experience, who reported examining 33.3 ± 31.0 dry eye patients per month. Forty-eight percent of respondents were involved in the p... Although dry eye disease was perceived to be an important condition, opinions varied widely regarding knowledge and confidence in diagnosis and management. Involvement in an extended service did not a...

Assessment of optometrists' referral accuracy and contributing factors: A review.

In the UK, ophthalmology has the highest number of outpatient appointments within the National Health Service. False-positive referrals from primary care are one of the main factors contributing to th... Of the 31 studies included in the review, 22 were retrospective analyses of referrals and appointments at the HES. Eight were prospective studies, and one used online clinical vignettes. Seven assesse... There was significant variation in referral accuracy across different ocular conditions, partly due to differences when defining accurate referrals. Optometrists working in primary care are generally ...

Prescribing patterns of myopia control contact lenses among optometrists in Ireland.

This retrospective analysis of electronic medical record (EMR) data investigated the prescribing patterns of soft myopia control contact lens (MCCL) treatments since their introduction in Ireland in 2... Anonymised EMR data were sourced from 33 optometry practices in Ireland from 2017 to 2021 to determine the number of practices prescribing MCCLs to myopic children 5-18 years old. In MCCL-prescribing ... Overall, just 10 practices were found to prescribe MCCLs of any type. The Coopervision MiSight contact lens was used in 85% of all MCCL fittings with most other fits being off-label multifocals. The u... Clinician engagement in myopia management has increased in Ireland since the formal introduction of MCCLs, but more than two-thirds of practices included are yet to offer this form of myopia managemen...

Opting out of Medicare: Characteristics and differences between optometrists and ophthalmologists.

To determine the rate of Medicare opt-out among optometrists and ophthalmologists and to contrast the differences in the characteristics and geographic distribution of these populations.... A retrospective cross-sectional study.... Using a publicly available Centers for Medicare & Medicaid Services (CMS) data set, we collated data for ophthalmologists and optometrists who opted out in each year between 2005 and 2023. We calculat... Both annual and cumulative rate of ophthalmologist and optometrist opt-out from Medicare.... The estimated prevalence of Medicare opt-outs was 0.52% (77/14,807) for ophthalmologists and 0.38% (154/40,526) for optometrists. Ophthalmologists opting out were predominantly male (67.5%), had a lon... Few ophthalmologists and optometrists opt-out of Medicare but this trend has significantly increased since 2012. Of those who disenrolled from Medicare, 83% of ophthalmologists were in urbanized areas...

Three-year outcomes of an optometrist-led virtual clinic for new glaucoma referrals.

The purpose of this study was to describe and evaluate the outcomes of an optometrist-led virtual glaucoma clinic (VGC).... New patients referred to the glaucoma service who were consultant triaged as 'low risk' were assessed virtually by specialist-trained optometrists in the VGC and either discharged or monitored for a p... A total of 1710 new patients were seen in the clinic between 1 January 2014 and 31 December 2016. Of these, 1033 (60.4%) patients required no outpatient input in 3 years of follow-up. Additionally, 32... This optometrist-led VGC combined two aspects of novel service delivery to reduce the burden of glaucoma monitoring in outpatient departments and consolidate consultant contact to patients requiring m...